Skip to main content
SpringerLink
Log in

Safety of Proton Pump Inhibitors: Current Evidence for Osteoporosis and Interaction with Antiplatelet Agents

  • Published:
Current Gastroenterology Reports Aims and scope Submit manuscript

Abstract

Proton pump inhibitors (PPIs) are commonly used in millions of patients. Despite the widespread usage and favorable safety profile, much attention has focused recently on potential adverse events associated with use. One area of particular concern is the reported potential adverse effects on bone density, causing possible osteoporosis and related bone fractures. The low magnitude of the association (OR < 2), lack of experimental evidence documenting a mechanism, and inability to assess potential confounding factors limit statements regarding causality. The other area of particular concern has been the combined use with antiplatelet agents, in particular with clopidogrel. Several retrospective studies suggested an adverse cardiovascular outcome if clopidogrel was combined with PPIs. The theoretic concern was raised to a possible interference with the bioactivation of the prodrug via competitive interference for both drugs at the cytochrome P450 pathway. Although ex vitro studies suggested a possible effect and several retrospective analyses were supportive of an adverse clinical outcome, the more recent prospective controlled trial data do not support an adverse cardiovascular outcome. This report reviews the scientific hypothesis, biologic plausibility, and the most recent clinical trial data for both areas of controversy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance, •• Of major importance

  1. Vestergaard P, Rejnmark L, Mosekilde L: Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 2006, 79:76–83.

    Article  CAS  PubMed  Google Scholar 

  2. Yang YX, Lewis JD, Epstein S, et al.: Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006, 296:2947–2953.

    Article  CAS  PubMed  Google Scholar 

  3. Targownik LE, Lix LM, Metge CJ, et al.: Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ 2008, 179:319–326.

    PubMed  Google Scholar 

  4. Bo-Linn GW, Davis GR, Buddrus DJ, et al.: An evaluation of the importance of gastric acid secretion in the absorption of dietary calcium. J Clin Invest 1984, 73:640–647.

    Article  CAS  PubMed  Google Scholar 

  5. Recker RR: Calcium absorption and achlorhydria. N Engl J Med 1985, 313:70–73.

    Article  CAS  PubMed  Google Scholar 

  6. O'Connell MB, Madden DM, Murray AM, et al.: Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med 2005, 118:778–781.

    Article  PubMed  CAS  Google Scholar 

  7. Serfaty-Lacrosniere C, Wood RJ, Voytko D, et al.: Hypochlorhydria from short-term omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans. J Am Col Nutr 1995, 14:364–368.

    CAS  Google Scholar 

  8. Graziani G, Como G, Badalamenti S, et al.: Effect of gastric acid secretion on intestinal phosphate and calcium absorption in normal subjects. Nephrol Dialysis Transplant 1995, 10:1376–1380.

    CAS  Google Scholar 

  9. Tuukkanen J, Vaananen HK: Omeprazole, a specific inhibitor of H+-K+-ATPase, inhibits bone resorption in vitro. Calc Tissue Int 1986, 38:123–125.

    Article  CAS  Google Scholar 

  10. Targownik LE, Lix LM, Leung S, Leslie WD: Proton pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology 2010, 138:896–904.

    Article  CAS  PubMed  Google Scholar 

  11. •• Laine L: Proton pump inhibitors and bone fractures? Am J Gastroenterol 2009, 104:S21–S26. This article is an excellent overview of the literature and evidence-based assessment of relative risks.

  12. Varenhorst C, James S, Erlinge D, et al.: Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. Euro Heart J. 2009, 30:1744–1752.

    Article  CAS  Google Scholar 

  13. Shuldiner AR, O’Connell JR, Bliden KP, et al.: Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009, 302:848–858.

    Article  Google Scholar 

  14. Gilard M, Arnaud B, Cornily JC , et al.: Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (omeprazole clopidogrel aspirin) study. J Am Coll Cardiol 2008, 51:256–260.

    Article  CAS  PubMed  Google Scholar 

  15. Small DS, Farid NA, Payne CD, et al.: Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol 2008, 48:475–484.

    Article  CAS  PubMed  Google Scholar 

  16. Gilard M, Arnaud B, Le Gal G, et al.: Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin [letter]. J Thromb Haemost 2006, 4:2508–2509.

    Article  CAS  PubMed  Google Scholar 

  17. Gilard M, Arnaud B, Cornily J-C, et al.: Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin. J Am Coll Cardiol 2008, 51:256–260.

    Article  CAS  PubMed  Google Scholar 

  18. Moceri P, Drogoul L, Ferrari E: Strong decrease of the clopidogrel antiplatelet effect with esomeprazole, but not with ranitidine and recovering of the antiplatelet effect by doubling the dosage of clopidogrel [abstract 895]. Euro Heart J 2009, 30(Suppl):150.

    Google Scholar 

  19. Siller-Matula JM, Spiel AO, Lang IM, et al.: Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 2009, 157:148.e1–148.e5.

    Google Scholar 

  20. Sibbing D, Morath T, Stegherr J, et al.: Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 2009, 101:714–719.

    CAS  PubMed  Google Scholar 

  21. •• O’Donoghue ML, Braunwald E, Antman EM, et al.: Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009, 374:989–997. This is a key article of two prospective trials with combined clopidogrel and PPI usage and assessment of cardiac outcomes. Although the PPI use was not an a priori risk assessment (and only one third of the study cohort took these), there is prospective data with excellent balance of stratified risks between groups.

  22. • Sibbing D, Kastrati A: Risk of combining PPIs with thienopyridines: fact or fiction? Lancet 2009, 374, 952–954. This article is a good summary editorial of the two prospective trials with clopidogrel and patients who also were taking PPIs.

  23. Dunn SP, Macaulay TE, Brennan DM, et al.: Baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO trial [abstract 3999]. Circulation 2008, 118(Suppl 2):S815.

    Google Scholar 

  24. Stanek EJ, Aubert RE, Flockhart DA, et al.: A national study of the effect of individual proton pump inhibitors on cardiovascular outcomes in patients treated with clopidogrel following coronary stenting: the Clopidogrel Medco Outcomes Study [late-breaking clinical trial O-11]. Presented at the 2009 Annual Scientific Session of the Society for Cardiovascular Angiography and Interventions. Las Vegas, NV; May 6–9, 2009.

  25. Dunn SP, Macaulay TE, Brennan DM, et al.: Baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO trial [abstract 3999]. Circulation 2008, 118(Suppl 2):S815.

    Google Scholar 

  26. Aubert RE, Epstein RS, Teagarden JR, et al.: Proton pump inhibitors effect on clopidogrel effectiveness: the Clopidogrel Medco Outcomes Study [abstract 3998]. Circulation 2008, 118(Suppl 2):S815.

    Google Scholar 

  27. Jarai R, Brosovic I, Tentzeris I, et al.: Effects of proton-pump inhibitors on outcome of patients discharged on dual-antiplatelet therapy after percutaneous coronary intervention and stent implantation [abstract P675]. Euro Heart J 2009, 30(Suppl):98.

    Google Scholar 

  28. Rossini R, Nijaradze T, Musumeci G, et al.: Safety of proton-pump inhibitors in patients on oral antiplatelet therapy with aspirin and clopidogrel after DES implantation [abstract P4532]. Euro Heart J 2009, 30(Suppl):741.

    Google Scholar 

  29. Simon T, Quandalle PH, Machecourt J, et al.: Proton pump inhibitors and clopidogrel response on cardiovascular major events inpatients after acute myocardial infarction. Data from the FAST-MI registry of the French Society of Cardiology [abstract P2121]. Euro Heart J 2009, 30(Suppl):335.

    Google Scholar 

  30. Simon T, Verstuyft C, Mary-Krause M, et al.: Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009, 360:363–375.

    Article  CAS  PubMed  Google Scholar 

  31. •• Bhatt DL, Cryer B, Contant CF, et al., on Behalf of the COGENT Investigators: The COGENT trial. Presented at the Transcatheter Cardiovascular Therapeutics Meeting. San Francisco, CA; September 21–25, 2009. This was a late-breaking abstract, so no published citation but a key article is forthcoming, as this will be the first prospective, randomized, controlled clinical trial assessing both cardiac and GI adverse events.

  32. Sweeny JM, Kini A, Muntner P, et al.: Mortality associated with proton pump inhibitors following percutaneous coronary interventions with drug eluting stents [abstract 4323]. Circulation 2009, 120:S936.

    Google Scholar 

  33. Ray WA, Murray KT, Griffin MR, et al.: Outcomes with concurrent use of clopidogrel with proton pump inhibitors. Ann Intern Med 2010, 152:337–355.

    PubMed  Google Scholar 

  34. Mega JL, Close Sl, Wiviott SD , et al.: Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 2009, 360:354–362.

  35. American College of Cardiology (ACC)/American College of Gastroenterology (ACG)/American Heart Association (AHA) joint comment on studies regarding possible interaction of clopidogrel and proton pump inhibitors [news release]. American College of Cardiology News Release; November 12, 2008. Available at http://www.acc.org/media/releases/highlights/2008/nov08/ppi.htm. Accessed February 2010.

  36. Society for Cardiovascular Angiography and Interventions: SCAI Statement on “A national study of the effect of individual proton pump inhibitors on cardiovascular outcomes in patients treated with clopidogrel following coronary stenting: the clopidogrel Medco outcomes study.” Washington, DC: Society for Cardiovascular Angiography and Interventions; 2009. Available at http://www.scai.org. Accessed February 2010.

  37. US Food and Drug Administration: Early communication about an ongoing safety review of clopidogrel bisulfate (marketed as Plavix). Available at http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm079520.htm. Accessed February 2010.

  38. National Prescribing Centre: EMEA statement on possible interaction between clopidogrel and proton pump inhibitors. Available at http://www.npci.org.uk/blog/?p=354. Accessed February 2010.

  39. US Food and Drug Administration: Follow-up to the January 26, 2009, early communication about an ongoing safety review of clopidogrel bisulfate (marketed as Plavix) and omeprazole (marketed as Prilosec and Prilosec OTC). Available at http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm190784.htm. Accessed February 2010.

  40. Würtz M, Grove EL, Kristensen SD, Hvas AM: The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease. Heart (British Cardiac Society) 2010, 96:368–371.

    Google Scholar 

  41. Shore PA, Brodie BB, Hogben CA: The gastric secretion of drugs: a pH partition hypothesis. J Pharmacol Exp Ther 1957, 110:361–369.

    Google Scholar 

  42. Hollander D Dadufalza VD, Fairchild PA: Intestinal absorption of aspirin. Influence of pH, taurocholate, ascorbate and ethanol. J Lab Clin Med 1981, 98:591–598.

    PubMed  Google Scholar 

  43. Giraud MN, Sanduja SK, Felder TB, et al.: Effect of omeprazole on the bioavailability of unmodified and phospholipid-complexed aspirin in rats. Aliment Pharmacol Ther 1997, 11:899–906.

    Article  CAS  PubMed  Google Scholar 

  44. Fernandez-Fenrandez FJ. Might proton pump inhibitors prevent the antiplatelet effects of low-or very low-dose aspirin? Arch Intern Med 2002, 162:2248.

    Article  Google Scholar 

  45. Saw J, Brennan DM, Steinhubl SR, et al.: Lack of Evidence of a Clopidogrel–Statin Interaction in the CHARISMA Trial. J Am Coll Cardiol 2007, 50:291–295.

    Article  CAS  PubMed  Google Scholar 

  46. •• Bhatt D, Scheiman J, Abraham N, et al.: ACCF/ACG/AHA Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID use. Am J Gastroenterol 2008, 103:2890–2907. This article is an excellent evidence-based consensus between the cardiology and GI societies to highlight the need for appropriate risk assessment for GI adverse outcomes and appropriate use of prophylaxis to protect against antiplatelet/NSAID GI injury.

Download references

Disclosure

Dr. Johnson has received research support from AstraZeneca and Takeda; has served as a consultant to AstraZeneca, Novartis, Eisai, and XenoPort; and has served on the adjudication committee for Eisai. No other potential conflict of interest relevant to this article was reported.

Author information

Authors and Affiliations

  1. Division of Gastroenterology, Eastern Virginia Medical School, 885 Kempsville Road, Suite 114, Norfolk, VA, 23505, USA

    David A. Johnson

Authors
  1. David A. Johnson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David A. Johnson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Johnson, D.A. Safety of Proton Pump Inhibitors: Current Evidence for Osteoporosis and Interaction with Antiplatelet Agents. Curr Gastroenterol Rep 12, 167–174 (2010). https://doi.org/10.1007/s11894-010-0103-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11894-010-0103-6

Keywords

Search

Navigation